EUVIMEDEUVIMED entdecken
Crossref

Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy

Ofek Raviv

NCODA Oncology and Hematology Meeting Abstracts · 07.04.2026

DOI: 10.67209/octx2598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 07.04.2026. Verfasst von Ofek Raviv. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer, accounting for 15–25% of all VTE cases. Cancer patients have a 4- to 7-fold higher risk of VTE than the general population. Historically, low-molecular-weight heparin (LMWH) was the standard for prophylaxis and treatment. Since 2018, randomized trials and meta-analyses evaluated direct oral anticoagulants (DOACs), leading to updated recommendations from the National Comprehensive Cancer Network and the American Society of Hematology for their use in cancer-associated VTE.

Zitieren

APA

Raviv, O. (2026). Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/octx2598

Vancouver

Raviv O. Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/octx2598

BibTeX
@article{Raviv2026,
  author = {Raviv, Ofek},
  title = {Direct oral anticoagulants in cancer-associated thrombosis: redefining extended therapy},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  doi = {10.67209/octx2598}
}
Kostenlos starten →